murf-1

MuRF1-IN-1 is an inhibitor of muscle ring finger 1.

MuRF1-IN-2 (Example 3) is a MuRF1 inhibitor used to study conditions linked to muscle wasting, encompassing both skeletal and cardiac muscle atrophy [1].

Smurf-1 modulator CMP Example 20 (Smurf-1-IN-20) is a potent Smurf-1 modulator.

Smurf1-IN-A01 (A01) is a ubiquitin ligase Smad ubiquitination regulatory factor-1 inhibitor (Kd: 3.664 nM) that enhances BMP-2 responsiveness by preventing Smurf1-mediated Smad1/5 degradation.

Smurf1 ligand 1 serves as a PROTAC target protein ligand (Ligands for Target Protein for PROTACs) and is utilized in synthesis.

Smurf1-IN-5 (Compound cpd-6) is an inhibitor of the SMAD ubiquitin regulatory factor (SMURF1). It reduces the ubiquitination of substrates such as BMPR2 (bone morphogenetic protein receptor 2) and SMAD1, thereby enhancing the BMP (bone morphogenetic protein) signaling pathway. Smurf1-IN-5 holds promise for research in pulmonary arterial hypertension (PAH).

AC430 is a potent and specific small molecule inhibitor of janus kinase 2 (JAK2), which has been implicated as a target for therapy in both oncology and autoimmune disease. AC430 is currently being developed by Ambit. In preclinical studies, AC430 has exhibited potency against JAK2 and V617F mutated JAK2 in cell-based models that is at least equivalent to, and in most cases superior to, competing JAK2 inhibitors. In preclinical oncology and autoimmune models, AC430 is well tolerated and has significant efficacy at oral doses as low as 10 mg/kg/day.

Smurf1 inhibitor 1 is a inhibitor that promotes bone formation.

Smurf1-IN-1, a selective E3 ubiquitin protein ligase 1 (SMURF1) inhibitor, exhibits oral activity with an IC50 of 92 nM and demonstrates considerable efficacy in a rat model of pulmonary hypertension [1].

MurF-IN-1 (Compound 7) is an inhibitor of the MurF enzyme, with a pIC50 value of 5.19 in assays targeting Streptococcus pneumoniae MurF [1].